Loading...
01/11 11:31
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with a 10% increase in net product revenue and disciplined cost control. The Q&A section reveals positive sentiment towards new patient starts and physician confidence, supported by promising ASCO data. Despite some uncertainties in portfolio diversification and economic conditions, the company's strong cash position and strategic focus on OJEMDA provide a positive outlook. Given the market cap of $1.2 billion, the stock price is likely to see a positive movement of 2% to 8% over the next two weeks.
Net Product Revenue for Q2 2025 $33.6 million, up 10% over the first quarter. The increase is attributed to strong physician adoption, sustained patient demand, and a 15% quarter-over-quarter growth in prescriptions.
Trailing 12-Month Net Revenue $113.1 million, reflecting significant and consistent growth with a compound quarterly growth rate of 22%. This growth is driven by strong demand, high payer coverage, and increased physician confidence.
Total Costs and Operating Expenses for Q2 2025 $68.9 million, which includes $10.9 million in noncash stock-based compensation. This represents a 5% decrease quarter-over-quarter, attributed to disciplined execution and cost control.
Net Cash Used in Operating Activities for Q2 2025 Decreased approximately 50% quarter-over-quarter, reflecting disciplined execution and a focus on cost control.
Cash Position at End of Q2 2025 $453 million with no debt, indicating a strong financial position to advance priorities and capitalize on opportunities.
OJEMDA approval and performance: OJEMDA has been approved for one year and has exceeded expectations with $113.1 million in cumulative net revenue over the past 12 months. It achieved $33.6 million in net product revenue in Q2 2025, marking a 10% growth over Q1. Over 1,000 prescriptions were filled in Q2, and the company projects $140-$150 million in net revenues for 2025.
FIREFLY-2 trial and EMA approval: The FIREFLY-2 confirmatory first-line trial is on track for enrollment completion in H1 2026. Ipsen, the company's partner, has filed for EMA approval for OJEMDA in Europe, with potential approval expected by mid-2026.
Portfolio updates: The company discontinued its VRK1 program but is advancing its PTK7-targeted ADC, DAY301, through Phase Ia trials. It is also exploring new portfolio expansion opportunities.
Market adoption of OJEMDA: OJEMDA has seen strong adoption with 15% quarter-over-quarter growth in prescriptions. Over 95% of patients are paid patients, and 90% receive approval upon initial submission. The drug is gaining traction as a second-line treatment for BRAF-altered pLGG.
Geographic expansion: The company is working with Ipsen to expand OJEMDA's reach in Europe, with EMA approval anticipated in mid-2026.
Revenue growth and financial position: The company achieved $33.6 million in Q2 revenue, a 10% increase from Q1. It has a strong financial position with $453 million in cash and no debt, enabling continued investment in trials and commercialization.
Operational efficiencies: Operating expenses decreased by 5% quarter-over-quarter, and net cash used in operations dropped by 50%, reflecting disciplined cost management.
Strategic focus on OJEMDA: The company is focused on establishing OJEMDA as the standard of care for second-line pLGG and expanding its indications. It is leveraging AI and prescriber insights to optimize commercialization.
Discontinuation of VRK1 program: The company has strategically discontinued its VRK1 program to focus on more promising opportunities like DAY301 and OJEMDA.
Regulatory Approval Timelines: The FIREFLY-2 trial for OJEMDA in frontline pLGG is on track for completion of enrollment in the first half of 2026, and EMA approval is expected mid-2026. Delays in these timelines could impact the company's ability to expand indications and revenue growth.
Market Penetration Challenges: Despite strong growth, many eligible patients have yet to receive OJEMDA, indicating challenges in achieving full market penetration and adoption.
Dependence on New Patient Starts and Therapy Persistence: Revenue growth is heavily dependent on the pace of new patient starts and persistence on therapy. Any slowdown in these areas could adversely affect financial performance.
Portfolio Diversification Risks: The company recently discontinued its investment in the VRK1 program, narrowing its portfolio. While advancing DAY301, the company remains reliant on OJEMDA for the majority of its revenue.
Economic and Market Conditions: The company highlighted the importance of disciplined cost control and capital allocation, indicating sensitivity to challenging market conditions that could impact operational flexibility.
Physician Adoption and Confidence: The company is working to build clinical evidence and encourage physician adoption of OJEMDA. Any failure to strengthen physician confidence could limit the drug's market potential.
Supply Chain and Payer Coverage: While payer coverage is currently strong, any disruptions in supply chain or changes in payer policies could negatively impact patient access and revenue.
Revenue Guidance for 2025: Day One Biopharmaceuticals projects total net revenues of between $140 million and $150 million for the full year 2025, reflecting strong demand, deepening prescriber adoption, and consistent payer coverage.
OJEMDA Commercialization and Expansion: The company is focused on establishing OJEMDA as the standard of care in second-line plus pLGG and pursuing significant potential indication expansion for OJEMDA in frontline pLGG through the FIREFLY-2 trial and in second-line plus pLGG in Europe through Ipsen's MAA filing.
FIREFLY-2 Trial Timeline: The global FIREFLY-2 confirmatory first-line trial is on track for completion of enrollment in the first half of 2026.
EMA Approval for OJEMDA: Potential EMA approval for OJEMDA is expected by mid-2026, following Ipsen's filing of an MAA.
DAY301 Development: The company is advancing its PTK7-targeted ADC, DAY301, through the dose escalation portion of its Phase Ia trial.
3-Year Follow-Up Data for FIREFLY-1: Day One plans to release 3-year follow-up data for FIREFLY-1, including additional efficacy and safety analyses, in the fourth quarter of 2025.
The selected topic was not discussed during the call.
The earnings call shows strong financial performance with a 15% QoQ revenue increase and an 89% YoY growth, alongside strategic product developments and expansion plans. Despite some uncertainties in data maturity and profitability guidance, the company's solid cash position and reduced operating expenses highlight financial discipline. The Q&A session reflects management's cautious optimism, with positive updates on trial progress and market expansion. Given the market cap of approximately $1.2 billion, the stock is likely to react positively, with potential gains in the 2% to 8% range over the next two weeks.
The earnings call highlights strong financial performance with a 10% increase in net product revenue and disciplined cost control. The Q&A section reveals positive sentiment towards new patient starts and physician confidence, supported by promising ASCO data. Despite some uncertainties in portfolio diversification and economic conditions, the company's strong cash position and strategic focus on OJEMDA provide a positive outlook. Given the market cap of $1.2 billion, the stock price is likely to see a positive movement of 2% to 8% over the next two weeks.
The earnings call indicates positive financial performance with net revenue growth and better-than-expected EPS. The cash position is strong with no debt, reducing financing risks. The Q&A session confirms steady patient adoption and management's confidence in market positioning. Despite competitive pressures and regulatory challenges, the company's strategic focus on pipeline expansion and business development is promising. The positive sentiment is tempered slightly by management's lack of clarity on certain trial details, but overall, the financial health and strategic initiatives suggest a positive stock price movement in the short term.
The earnings call highlights a strong financial performance with 11% revenue growth for OJEMDA, a solid cash position of $473 million, and no debt. The strategic focus on pipeline advancement and market expansion is promising. Although there are macroeconomic risks and competitive pressures, the company maintains disciplined financial management. The Q&A section reveals optimism about patient retention and market penetration. While some management responses were unclear, the overall sentiment is positive, suggesting a stock price increase of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
